for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alexion Pharmaceuticals, Inc.

ALXN.OQ

Latest Trade

105.67USD

Change

2.69(+2.61%)

Volume

744,006

Today's Range

103.27

 - 

106.24

52 Week Range

92.57

 - 

141.81

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
102.98
Open
103.65
Volume
744,006
3M AVG Volume
50.43
Today's High
106.24
Today's Low
103.27
52 Week High
141.81
52 Week Low
92.57
Shares Out (MIL)
224.23
Market Cap (MIL)
23,090.88
Forward P/E
10.38
Dividend (Yield %)
--

Next Event

Q3 2019 Alexion Pharmaceuticals Inc Earnings Release

Latest Developments

More

Alexion And Bridgebio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis Investigational Medicine

Alexion Pharmaceuticals Says European Patent Office To Not Grant Co Patent Application Relating To Pharmaceutical Composition Of Soliris

Alexion Pharmaceuticals Q2 Non-GAAP Earnings Per Share $2.64

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Industry

Major Drugs

Contact Info

121 Seaport Blvd

+1.475.2302596

http://alexion.com/

Executive Leadership

David R. Brennan

Independent Chairman of the Board

Ludwig N. Hantson

Chief Executive Officer, Director

Paul J. Clancy

Chief Financial Officer, Executive Vice President

Indrani Franchini

Executive Vice President, Chief Compliance Officer

Ellen Chiniara

Executive Vice President, General Counsel, Corporate Secretary

Key Stats

1.95 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

3.1K

2017

3.6K

2018

4.1K

2019(E)

4.8K
EPS (USD)

2016

4.620

2017

5.860

2018

7.920

2019(E)

9.924
Price To Earnings (TTM)
18.75
Price To Sales (TTM)
5.13
Price To Book (MRQ)
2.27
Price To Cash Flow (TTM)
14.12
Total Debt To Equity (MRQ)
26.03
LT Debt To Equity (MRQ)
24.73
Return on Investment (TTM)
9.53
Return on Equity (TTM)
8.83

Latest News

Patent court to review Alexion's Soliris patents on Amgen challenge

The U.S. patent office will review patents on Alexion Pharmaceuticals Inc's blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday.

Patent court to review Alexion's Soliris patents on Amgen challenge - filings

The U.S. patent office will review three patents on Alexion Pharmaceuticals Inc's drug Soliris, after rival Amgen Inc filed a petition challenging them, court filings showed on Friday.

Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe

Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones.

Alexion wins early U.S. approval for rare blood disorder drug

The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc's rare blood disorder drug Ultomiris, an early backing that also solidifies the company's dominant market position.

U.S. FDA approves Alexion Pharma's blood disorder drug

The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc's blood disorder drug Ultomiris, the pharma regulator's website showed https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108 on Friday.

Alexion to buy biotech firm Syntimmune for up to $1.2 billion

Alexion Pharmaceuticals Inc <ALXN.O> said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, bolstering its portfolio of drugs to treat rare disorders.

Alexion to buy biotech firm Syntimmune for up to $1.2 bln

Alexion Pharmaceuticals Inc said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, giving it access to a rare blood disorder drug.

BRIEF-Alexion Reports Q1 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study

* ALEXION REPORTS FIRST QUARTER 2018 RESULTS AND POSITIVE TOPLINE DATA FROM ALXN1210 PHASE 3 PNH SWITCH STUDY

BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil

* ALEXION PROVIDES STATEMENT ON SUPERIOR COURT OF JUSTICE (STJ) DECISION IN BRAZIL INVOLVING SOLIRIS® (ECULIZUMAB)

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:

Biotech M&A rolls on as Alexion snaps up Wilson for $855 million

Alexion Pharmaceuticals <ALXN.O> has agreed to buy Sweden's Wilson Therapeutics <WTX.ST> for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues.

Alexion to buy Swedish biotech Wilson Therapeutics for $855 mln

Alexion Pharmaceuticals said on Wednesday it had agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million) to boost its line-up of rare disease drugs.

BRIEF-Alexion To Acquire Wilson Therapeutics

* SAYS ALEXION WILL ACQUIRE WILSON THERAPEUTICS THROUGH A TENDER OFFER

BRIEF-Alexion Pharmaceuticals Says CEO Ludwig Hantson's Total FY 2017 Compensation Was $15.3 Mln

* ALEXION PHARMACEUTICALS SAYS CEO LUDWIG HANTSON'S TOTAL FY 2017 COMPENSATION WAS $15.3 MILLION - SEC FILING

Alexion's second rare blood disorder drug could fortify future revenue

Alexion Pharmaceuticals Inc said its experimental drug to treat a rare blood disorder showed in an eagerly awaited study that it was not inferior to its flagship drug, Soliris, paving the way for the company to establish a dominant position in the market as competition looms...

BRIEF-Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210

* ALEXION ANNOUNCES POSITIVE TOP-LINE RESULTS SHOWING SUCCESSFUL PHASE 3 CLINICAL STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

Alexion's rare blood disorder drug succeeds in late-stage study

Alexion Pharmaceuticals Inc said its experimental drug, ALXN1210, met the main goal in a late-stage study in patients with a rare blood disorder.

BRIEF-Alexion Pharma Q4 GAAP Earnings Per Share $0.13

* ALEXION REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND PROVIDES FINANCIAL GUIDANCE FOR 2018

Alexion, Elliott to jointly look for new director

Alexion Pharmaceuticals Inc said on Tuesday it had agreed to work with hedge fund Elliott Management to identify a new member to join the drugmaker's board.

BRIEF-Alexion And Elliott Agree To Collaborate On Identifying A New Board Member

* ALEXION AND ELLIOTT AGREE TO COLLABORATE ON IDENTIFYING A NEW BOARD MEMBER

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up